Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC

MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

(2020) Ibiayi Dagogo-Jack et al.   CLINICAL CANCER RESEARCH

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non–Small Cell Lung Cancer

(2020) Terry L. Ng et al.   Journal of Thoracic Oncology

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

(2020) Todd M. Bauer et al.   Targeted Oncology

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners

(2020) Mollie Reed et al.   ADVANCES IN THERAPY

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

(2020) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

(2020) Viola W. Zhu et al.   Journal of Thoracic Oncology

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

(2020) Kyriakos P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

A user’s guide to lorlatinib

(2020) Misako Nagasaka et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

(2020) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression

(2020) S.I. Ou et al.   ANNALS OF ONCOLOGY

Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study

(2020) Tony Mok et al.   Journal of Thoracic Oncology

ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

(2020) G. Selvaggi et al.   Journal of Thoracic Oncology

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

(2020) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

(2019) Koutaroh Okada et al.   EBioMedicine

Clinical Management of Adverse Events Associated with Lorlatinib

(2019) Todd M. Bauer et al.   ONCOLOGIST

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study

(2019) D. Ross Camidge et al.   Journal of Thoracic Oncology

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

(2019) Caicun Zhou et al.   Lancet Respiratory Medicine

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

(2019) Ibiayi Dagogo-Jack et al.   CLINICAL CANCER RESEARCH

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer

(2019) Leora Horn et al.   Journal of Thoracic Oncology

Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors

(2019) Jessica J. Lin et al.   Journal of Thoracic Oncology

P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)

(2019) R. Garcia Campelo et al.   Journal of Thoracic Oncology

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

(2019) Maurice Pérol et al.   LUNG CANCER

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

(2019) Kazuhiko Nakagawa et al.   LUNG CANCER

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

(2019) Yunpeng Yang et al.   Lancet Respiratory Medicine

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

(2018) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers

(2018) Alexander Drilon et al.   Journal of Thoracic Oncology

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer

(2018) Makoto Nishio et al.   LUNG CANCER

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

(2018) Leila Dardaei et al.   NATURE MEDICINE

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

(2018) Satoshi Yoda et al.   Cancer Discovery

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

(2018) S Gadgeel et al.   ANNALS OF ONCOLOGY

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

(2018) D. Ross Camidge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

(2018) Benjamin J Solomon et al.   LANCET ONCOLOGY

Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer

(2018) Jose M. Pacheco et al.   Journal of Thoracic Oncology

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

(2017) Dong-Wan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib

(2017) Trish Thorne-Nuzzo et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

(2017) Michaël Duruisseaux et al.   Oncotarget

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

(2016) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE